The R239G mutation occurs at a significantly higher frequency compared with other novel mutations and can manifest across all stages, particularly prominent during the remission stage in BCR::ABL1‐Positive ALL subjects. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.